Endpoints News

Syncromune, a Florida cancer biotech, raises $100M in an impressive Series A.

Some Friday-before-Christmas health tech news: (General Catalyst-backed) Commure is making another acquisition, this time buying (General Catalyst-backed) Memora Health, Ngai Yeung reports https://lnkd.in/gPEy8qTb

FDA approves Ionis Pharmaceuticals, Inc.’ antisense oligonucleotide olezarsen, making it the first approved treatment for familial chylomicronemia syndrome, a rare metabolic disorder that prevents the body from breaking down triglycerides. https://lnkd.in/eMNSziUw

BREAKING: Novo Nordisk's CagriSema fails to hit 25% weightloss benchmark in Phase 3 readout. Novo’s stock $NVO crashed by as much as 26% pre-market Friday. https://lnkd.in/eiMBqxDd

We put out our last Endpoints News Health Tech newsletter of the year today! Inside: - We got a sense of what health tech funding looks like going into 2025 - Shelby Livingston has the latest on the tirzepatide shortage ending, and what that means for compounders Check it out: https://lnkd.in/gRdeMaCt

Just two months after an initial run for capital, David Epstein and team have stapled together a hefty $140 million Series A co-led by OrbiMed, Avoro Capital and Samsara BioCapital.

Roche’s AST antibody has failed to slow the progression of motor symptoms in a mid-stage Parkinson’s disease test, marking the latest setback in a largely challenging year for the disease pipeline.

It's the end of the year, which means it's time for the Endpoints News 2025 winners and losers list! Who was naughty, who was nice? 🎅 Featuring: 📩 An errant email 🐴 A horse 📱 Selling drugs online 🫠 The stock market ...and much, more more in #biotech, #pharma, #vc #healthtech, featuring Summit Therapeutics, Inc., Pfizer, Forbion, the Federal Trade Commission, Eli Lilly and Company + Novo Nordisk, Isomorphic Labs + many others! https://lnkd.in/ec7twgiS https://lnkd.in/ec7twgiS

The 2024 winners and losers in the pharma world are in. Who's up and who's down? Do you agree? Let us know in the comments. https://lnkd.in/ekxEzwR7

Exclusive: Bluenote has launched, raising $10M to fine-tune LLMs for the biopharma world. The SF startup is led by two Color Health alum, who were employees No. 1 and 2 at that health-tech startup: CEO Fatima Sabar and CTO Katsuya Noguchi. I talked to both of them for Endpoints News on what they're building and why they believe that LLMs, with the right tweaks, are now ready to upend much of the regulatory and compliance work in the drug industry. Elad Gil, one of Silicon Valley’s most active angel investors, led Bluenote's pre-seed round and Lux Capital led the seed. My latest: